menu description  

 

BENEFITS

  • With its unique TLC-NOSF* Healing Matrix (NOSF* impregnated in a TLC healing matrix) it is the only local treatment proven to reduce healing time (1,2,3,4)
  • The sooner the TLC-NOSF* treatment is initiated the short the healing time (5)
  • Significantly improves patients' quality of life (2,3)
  • Acts from Day 1 to complete healing, whatever the wound healing stage, simplifying treatment for clinicians and saving costs for healthcare systems (6)

*NOSF (Nano OligoSaccharide Factor) = KSOS (potassium sucrose octasulfate)

INDICATIONS

For all leg ulcers, diabetic foot ulcers, pressure ulcers and long standing acute wounds.

RANGE

Treatment to reduce healing time with the unique TLC-NOSF* Healing Matrix

UrgoStart Plus Pad and UrgoStart Plus Border also contain poly-absorbent  fibres which bind, trap and retain exudate, slough and debris present in the wound, keeping it clean throughout healing.

INSTRUCTIONS

  • Cleanse the wound bed as per your local protocol and rinse the wound with normal saline.
  • Dry the surrounding skin carefully.
  • Apply the soft-adherent side of UrgoStart Plus Pad or UrgoStart Plus Border directly to the wound (if using UrgoStart Plus Border the adhesive silicone border should be at least 1cm away from the wound). Apply UrgoStart contact directly to the wound. UrgoStart contact can also be used in cavity wounds and wounds in awkward areas.
  • If using UrgoStart Plus Pad or UrgoStart contact cover with a secondary dressing when necessary, suitable for the location and level of wound exudate, and secure it in place with a conforming bandage such as K-Band or K-Lite.
  • Apply a compression bandage system when prescribed.
  • Can be left in place for up to 7 days.

SIZES AVAILABLE

  Size NPC** Code PIP Code
UrgoStart Plus Pad

6 x 6 cm ELZ884 406-4432
10 x 10 cm ELZ885 406-4440
15 x 20 cm ELZ886 406-4457

  Size NPC** Code PIP Code
UrgoStart Plus Border 8 x 8 cm ELZ879 406-4390
10 x 10 cm ELZ880 406-4408
13 x 13 cm ELZ881 406-4416
15 x 20 cm ELZ882 406-4424
20 x 20 cm (sacrum) ELZ883 406-4887

  Size NPC** Code PIP Code
UrgoStart Contact layer 5 x 7 cm EKB081 339-8971
10 x 10 cm EKB087 386-1390
15 x 20 cm EKB088 386-1382

**NPC = NHS Supply Chain ordering code

 

REFERENCES

1. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153.

2. Meaume S. et al., Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7):
368-379.

3. Meaume S. et al., A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.

4. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.

5. Rayman G, Edmonds M, Lázaro-Martínez JL, Martini J, Lobmann R, Bohbot S, Piaggesi A. Sucrose Octasulfate Dressing versus Neutral Dressing in Patients with Diabetic Foot Ulcer: Results of a Prospective, European, Randomised, Double-blind, Controlled Trial (‘Explorer’). EWMA Krakow. May 10th 2018. Oral presentation.

6. An Economic Evaluation of UrgoStart® for Patients with Chronic Leg Ulcers in the United Kingdom. York University. Data on fi le. Urgo, 2011.